JNJ - Johnson & Johnson
| Previous close | 128.64 |
| Open | 128.61 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 800 |
| Day's range | 128.15 - 129.45 |
| 52-week range | 121.00 - 148.99 |
| Volume | 5,562,258 |
| Avg. volume | 7,190,596 |
| Market cap | 342.078B |
| Beta (3Y monthly) | 0.76 |
| PE ratio (TTM) | 21.40 |
| EPS (TTM) | 6.02 |
| Earnings date | 15 Oct 2019 |
| Forward dividend & yield | 3.80 (2.95%) |
| Ex-dividend date | 2019-08-26 |
| 1y target est | 149.28 |
- Motley Fool•9 hours ago
How to Invest in Cancer-Fighting Stocks
Seven steps to help you invest more effectively in the war on cancer.
- Zacks•14 hours ago
Biogen (BIIB) Up on Q2 Earnings & Sales Beat, Raised View
Biogen (BIIB) reports encouraging second-quarter results. Shares rise in pre-market trading.
- Zacks•16 hours ago
Will Humira & Other Drugs Drive AbbVie's (ABBV) Q2 Earnings?
Steady rise in demand for Humira in the United States and strong growth of Imbruvica are expected to drive AbbVie's (ABBV) second-quarter sales.
- Motley Fool•18 hours ago
3 of the Most Rock-Solid Dividend Stocks in the World
These income stocks look incredibly secure for a long time to come.
- Financial Times•20 hours ago
Drugmakers shell out record amount lobbying Congress
Drugmakers spent a record amount of money lobbying Congress in the first half of the year, trying to defend against the threat of drug pricing reforms that could hit their bottom line such as a new bill revealed by the Senate finance committee on Tuesday. The industry group Pharmaceutical Research and Manufacturers of America spent $16.1m on lobbying in the first half of this year, up 4 per cent from its previous record of $15.5m in the first half of 2018, according to congressional filings. PhRMA, which did not respond to a request for comment, also broke its record for a full year in 2018, dishing out $27.5m in total.
- Motley Fool•2 days ago
The 10 Biggest Blue Chip Stocks
These top-quality stocks lead their industries, and they've been good to investors over the long run.
- Zacks•2 days ago
The Zacks Analyst Blog Highlights: Microsoft, JPMorgan, Merck, Johnson & Johnson and IBM
The Zacks Analyst Blog Highlights: Microsoft, JPMorgan, Merck, Johnson & Johnson and IBM
- Zacks•2 days ago
Is a Beat in Store for AbbVie (ABBV) This Earnings Season?
Rising demand for Humira in the United States and strong growth of Imbruvica are expected to drive AbbVie's (ABBV) second-quarter sales.
- Zacks•2 days ago
Stocks Slip This Week on Earnings, Fed Uncertainties
Stocks Slip This Week on Earnings, Fed Uncertainties
- Motley Fool•2 days ago
Is Johnson & Johnson a Buy?
The pros and the cons for this giant healthcare stock.
- Zacks•5 days ago
The Zacks Analyst Blog Highlights: Johnson & Johnson, NextEra, Deere, Cintas and Canadian Pacific
The Zacks Analyst Blog Highlights: Johnson & Johnson, NextEra, Deere, Cintas and Canadian Pacific
- Zacks•5 days ago
Pharma Stock Roundup: JNJ & NVS' Q2 Earnings, Pipeline/Regulatory Updates in Focus
J&J (JNJ) and Novartis (NVS) set the earnings season in motion for the pharma space. FDA approves Merck's (MRK) new combination antibacterial injection, Recarbrio.
- Zacks•5 days ago
Dow 30 Stock Roundup: MSFT, JPM, IBM, JNJ, GS Earnings Impress
The Dow endured a volatile week, primarily due to renewed trade tensions, after gaining strongly earlier this month
- Zacks•6 days ago
3 Key Takeaways From J&J's (JNJ) Q2 Earnings Announcement
Here are some of the highlights of J&J's (JNJ) second-quarter earnings call.
- Zacks•6 days ago
Top Stock Reports for Johnson & Johnson, NextEra & Deere
Top Stock Reports for Johnson & Johnson, NextEra & Deere
- Market Realist•6 days ago
Litigation Looms in the Wake of JNJ’s Solid Q2 Earnings
Johnson & Johnson (JNJ) reported its second-quarter earnings results before the market opened on Tuesday.
- Motley Fool•6 days ago
5 Signs of Life in Johnson & Johnson's Second-Quarter Earnings Report
Investors worried about dwindling sales of key drugs and mounting litigation expenses have at least five reasons to stay calm.
- Zacks•7 days ago
Healthcare ETFs in Focus on JNJ's Q2 Earnings Beat
Johnson & Johnson beat the second-quarter earnings and revenue estimates but warned on competition from generics and biosimilars that could impact its third-quarter results.
- Financial Times•7 days ago
WHO declares emergency over Ebola epidemic in Congo
The World Health Organization has declared an international emergency over the Ebola epidemic in the Democratic Republic of Congo, which has killed more than 1,600 people over the past year and shows no sign of declining. Dr Tedros Adhanom Ghebreyesus, WHO director-general, announced that the outbreak was now a “public health emergency of international concern” after a meeting of the UN-affiliated organisation’s emergency committee in Geneva. “We need to work together in solidarity with the DRC to end this outbreak,” said Dr Tedros.
- Yahoo Finance•8 days ago
Johnson & Johnson CFO on the opioid crisis: 'We don’t believe we were the cause'
Pharmaceutical companies are facing increasing scrutiny for their alleged roles in the opioid crisis. Its next target? Johnson & Johnson (JNJ).
- Yahoo Finance•8 days ago
Stocks slip slightly amid trade remarks, earnings season
U.S. stocks were mixed Tuesday afternoon as investors digested a wave of signals from officials over U.S.-China trade relations and monetary policy, along with an influx of corporate earnings results and economic data.
Motley Fool•8 days agoJohnson & Johnson (JNJ) Q2 2019 Earnings Call Transcript
JNJ earnings call for the period ending June 30, 2019.
- Bloomberg•8 days ago
J&J Ups Sales Forecast as Cancer Drugs Drive Growth
(Bloomberg) -- Johnson & Johnson raised its revenue guidance for the year, as strong sales in its pharmaceutical unit helped cushion a decline in the consumer and medical technology businesses.Second-quarter adjusted earnings were $2.58 a share, topping the $2.45 average of analysts’ estimates. To read more details on the results, click here.Key InsightsThe company’s full revenue is actually down from a year prior. Part of that can be attributed to the company’s divestiture of its medical sterilization business, ASP, which it sold to Fortive Corp. earlier this year. The company was also hit badly by foreign exchange rates. Almost half of J&J’s sales come from outside the U.S., and its fastest-growing segment -- overseas pharmaceuticals -- had its growth cut nearly in half because of currency fluctuations.J&J’s drug business is the largest of the company’s three main segments and accounts for more than half of all revenue. Its cancer drugs, including Darzalex and Imbruvica, drove growth in the quarter and were up 9.8% from a year prior.Market ReactionThe shares were down 1% to $133.41 at 9:43 a.m. in New York. The stock is up 4.4% this year to date as of Monday’s close, trailing the broader market.(Corrects spelling of cancer drug Darzalex in “Key Insights” section.)To contact the reporter on this story: Riley Griffin in New York at rgriffin42@bloomberg.netTo contact the editor responsible for this story: Drew Armstrong at darmstrong17@bloomberg.netFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
- Zacks•8 days ago
AbbVie (ABBV) Acquires Mavupharma to Boost Cancer Portfolio
AbbVie (ABBV) buys Mavupharma to develop novel treatments for cancer using the latter's STING signaling pathway.
